Société Française de Cardiologie
Type de publication
Revue ACVD
acvd - article du mois - janvier 2023

Archives of Cardiovascular Diseases
Article du mois - Janvier 2023

Contenu de la publication

Patrick Henry, Bertrand Cariou, Michel Farnier, Sarah L. Lakhdari, Bruno Detournaye


Background. – Recently, a multicentre, prospective, single-arm, phase 3b, open-label trial was conducted
to determine the safety and efficacy of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting. This study enrolled patients at high cardiovascular risk, with heterozygous familial hypercholesterolaemia (HeFH) or non-familial hypercholesterolaemia (non-FH). Results showed that alirocumab was well tolerated and resulted in a clinically significant reduction in low-density lipoprotein cholesterol (LDL-C).

Aim. – This ancillary analysis aimed to describe the characteristics of the French patients enrolled in the study, the main results observed in this population according to their familial hypercholesterolaemia status, and adherence to treatment.

Methods. – French data were analysed separately from the original dataset of the study.

Results. – Among 215 French patients in the ODYSSEY APPRISE trial, 63.7% had non-FH, with a mean LDL-C concentration of 5.0 ± 1.8 mmol/L at baseline. The mean duration of alirocumab exposure was 72.4 ± 42.5 weeks, with only 48.4% of patients receiving statins concomitantly. At week 12, a mean reduction in LDL-C of 56.5 ± 17.8% was observed: 51.2 ± 22.8% in HeFH; 59.5 ± 13.2% in non-FH. This improvement in LDL-C started from week 4 and remained stable and sustained until week 120 in both populations. The overall incidence of severe treatment-emergent adverse events (TEAEs) was 33.5%. The most frequent TEAEs were myalgia (15.8%) and asthenia (15.3%). No tolerance or efficacy differences were observed between patients with or without established coronary artery disease or other cardiovascular disease, whatever the age of these events or considering the concomitant use of other lipid-lowering therapies.

Conclusions. – In the French setting, alirocumab was well tolerated, safe and highly effective at reducing LDL-C. These findings support the use of alirocumab to manage hypercholesterolaemia in patients at high cardiovascular risk.